News
StockStory.org on MSN15d
Why Regeneron (REGN) Stock Is Trading Up Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...
Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
StockStory.org on MSN4d
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest ...
Zacks.com on MSN1d
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...
Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per share. This compares to earnings of $11.56 per share a year ago. These ...
Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.
REGN Factor-Based Stock Analysis - Benjamin Graham June 25, 2025 — 02:07 pm EDT Written by John Reese for Validea -> ...
REGENERON PHARMACEUTICALS INC (REGN) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback